PHIBRO ANIMAL HEALTH CORP (PAHC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001069899 0001069899 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
How this was made
The 30-second read
Why it matters
The disclosure provides concrete incentive terms (base salary, bonus eligibility, and RSU vesting thresholds based on a 90-day average of PAHC’s closing price) that can influence how investors model management alignment and risk-taking.
Market read
This is a primary-source executive transition filing with specific equity-vesting conditions tied to PAHC’s stock-price range, which can drive short-term sentiment and positioning.
What to watch
Traders may over-weight the compensation headline; the more important catalysts will be any subsequent strategic updates, guidance, or operational performance under the new CEO.
Background
The 8-K (Item 5.02) reports the board’s approval of an employment agreement and a performance-based RSU award for incoming CEO Dani Bendheim effective July 1, 2026.
Ticker impact
Phibro Animal Health disclosed CEO Dani Bendheim’s July 1 start and a performance-vested RSU grant tied to a $70–$100 stock-price range.
Likely modest, sentiment-driven reaction around the appointment/compensation terms; follow-through depends on subsequent guidance and performance.
The filing is a primary-source 8-K with concrete compensation/vesting thresholds, but it does not include earnings, guidance, or operational milestones.
Market effects
Limited read-across to animal health peers; this is company-specific leadership and incentive design.
No clear regional spillover beyond Nasdaq-listed small/mid-cap sentiment.
No direct global macro or cross-border transaction disclosed.
Counterpoint
The RSU vesting is contingent on a long-dated stock-price average (through 2031), so the near-term trading impact may fade quickly.
Key entities
- companyPhibro Animal Health Corporation
Nasdaq-listed animal health company; disclosed CEO appointment and compensation/RSU vesting mechanics in an 8-K.
- executiveDaniel (Dani) Bendheim
Appointed Chief Executive Officer and President effective July 1, 2026; received 300,000 performance-based RSUs.
- boardCompensation Committee of the Board of Directors
Approved the employment agreement and RSU grant as part of the CEO transition.
